Group items tagged

The report is titled as' 'Surgical Robots Market: Opportunity Analysis and Future Assessment 2022-2030'. An overview of conceptual frameworks, analytical approaches of the surgical robots market is the main objective of the report, which further consists of the market opportunity and insights of the data involved in the making of the respective market. The surgical robots market is expected to grow at a significant rate in the near future. The surgical robots market size was valued at US$ 6.2 Bn in 2020 and is expected to expand at a compound annual growth rate (CAGR) of 18.2% from 2020 to 2028. Request a Sample Copy of this Report @: https://reportsandinsights.com/sample-request/4358 Surgical Robots Introduction The term 'Robotic surgery' has existed around for over a couple of decades now, and has been an incredible and a revolutionary effort in enhancing the surgical procedures and making the patients' experience lenient and pleasant. The employment of surgical robotics in medical interventions has become run-of-the-mill in the previous decade. With the widespread acknowledgement and acceptance in robotic surgery, the encouragement to offer minor, greater efficiency and low-cost equipment is propelling the researchers to reach unprecedented heights. Robotic surgery, in the present times, has been effectively put into practice in numerous hospitals across the world and has achieved global acceptance. Although robots were not born yesterday as it has been around for a very long time, only in the past few years have these machines and automatics arrived in the field of medicines and healthcare. Over a long period of time, robots have become enormously evolved in comparison to their antecedents. In today's times, robots have become highly precise, highly specific, and perfectly suited for dangerous and risky jobs, which just a few decades ago, had to be performed by the human workforce. This major evolution can be mainly attributed to the recent a

Stock in biotech company Medivation more than doubled in value after reports that their phase III study of a new drug to treat prostate cancer has showed major success.